Results 111 to 120 of about 15,279 (220)

Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010-2020. [PDF]

Vaccine, 2021
Chard AN, Martinez M, Matanock A, Kassem AM.   +3 more
europepmc   +1 more source

Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique. [PDF]

J Infect Dis, 2022
de Deus N, Capitine IPU, Bauhofer AFL, Marques S, Cassocera M, Chissaque A, Bero DM, Langa JP, Padama FM, Jeyaseelan V, Oberste MS, Estivariz CF, Verma H, Jani I, Mach O, Sutter RW.   +15 more
europepmc   +1 more source

Novel Oral Polio Vaccine Type 2 Use for Polio Outbreak Response: A Global Effort for a Global Health Emergency

Pathogens
A sharp rise in circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks in the years following the cessation of routine use of poliovirus type 2-containing oral polio vaccine and the trend of seeding new emergences with suboptimal vaccination ...
Feyrouz Damji Kurji, Ananda Sankar Bandyopadhyay, Simona Zipursky, Laura V. Cooper, Chris Gast, Margaret Toher, Ralf Clemens, Sue Ann Costa Clemens, Rayasam Prasad, Adriansjah Azhari   +9 more
doaj   +1 more source

Notes from the Field: Circulating Vaccine-Derived Poliovirus Type 2 Emergences Linked to Novel Oral Poliovirus Vaccine Type 2 Use - Six African Countries, 2021-2023. [PDF]

MMWR Morb Mortal Wkly Rep, 2023
Davlantes E, Jorba J, Henderson E, Bullard K, Deka MA, Kfutwah A, Martin J, Bessaud M, Shulman LM, Hawes K, Diop OM, Bandyopadhyay AS, Zipursky S, Burns CC.   +13 more
europepmc   +1 more source

Impediments to Progress Toward Polio Eradication During 2014–2024: Effectively Addressing the Current Challenges

Vaccines
When the Global Polio Eradication Initiative (GPEI) began in 1988, the year 2000 target was clearly ambitious. Nonetheless, among 20 countries with endemic wild poliovirus transmission in 2000, only Afghanistan, Nigeria and Pakistan remained endemic in ...
Steven G. F. Wassilak, Abdinoor Mohamed, John Paul Bigouette   +2 more
doaj   +1 more source

Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. [PDF]

Front Public Health, 2023
Thompson KM, Kalkowska DA, Badizadegan K.   +2 more
europepmc   +1 more source

Rare adverse events associated with oral poliovirus vaccine in Brazil

Brazilian Journal of Medical and Biological Research, 1997
Oral poliovirus vaccine (OPV) developed by A. Sabin has been effectively used to control poliomyelitis in Brazil, and the last case with the isolation of a wild poliovirus strain occurred in March 1989.
Friedrich F.
doaj  

Antiviral Development for the Polio Endgame: Current Progress and Future Directions

Pathogens
As the world is approaching the eradication of wild poliovirus serotype 1, the last of the three wild types, the question of how to maintain a polio-free world becomes imminent.
Hang Xie, Eric E. Rhoden, Hong-Mei Liu, Folake Ogunsemowo, Bernardo A. Mainou, Rachel M. Burke, Cara C. Burns   +6 more
doaj   +1 more source

Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation. [PDF]

Gates Open Res, 2023
Kalkowska DA, Wassilak SG, Wiesen E, F Estivariz C, Burns CC, Badizadegan K, Thompson KM.   +6 more
europepmc   +1 more source

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children. [PDF]

J Infect Dis, 2022
Tagbo BN, Verma H, Mahmud ZM, Ernest K, Nnani RO, Chukwubike C, Craig KT, Hamisu A, Weldon WC, Oberste SM, Jeyaseelan V, Braka F, Mkanda P, Esangbedo D, Olowu A, Nwaze E, Sutter RW.   +16 more
europepmc   +1 more source